GIM-621 is a preclinical-stage, first-in-class oral small molecule immunotherapy with potential application across multiple ...
Lunit Inc. (KRX: 328130) and Summit Therapeutics Inc. announced a research agreement to evaluate the use of Lunit SCOPE IO, ...
Harbour BioMed Secures China’s NMPA Approval for Batoclimab, Expanding Treatment Options for Myasthenia Gravis ...
Through its collaboration with OASES and partners across the healthcare ecosystem, Johnson & Johnson looks forward to: ...
Tairex, an AI healthcare technology company incubated by the Institute for AI Industry Research (AIR) at Tsinghua University, ...
Coreline Soft has received U.S. Food and Drug Administration (FDA) 510 (k) clearance for AVIEW Aorta Metrics, its AI-powered ...
Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), an innovation-driven, global biopharma company, shared the first data from a ...
Nine markets, six questions, one page to pin above the desk. From Japan's 50,000-patient line to China's brand-new seven-year exclusivity, this is what a rare disease developer actually gets across ...
Therakos Development Limited, a global pioneer in immunomodulatory therapy delivered at the bedside through extracorporeal ...
CellCarta Partners with Waters Corporation to Advance Companion Diagnostics and Next-Generation Flow Cytometry ...
New Phase II/III study will evaluate ivonescimab plus chemotherapy against existing immunotherapy-based treatments, building on positive overall survival results from the Phase III HARMONi-GI1 trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results